Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C21H35N8O6P |
| Molecular Weight | 526.5264 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)[C@H](C)NP(=O)(COCCN1C=NC2=C(NC3CC3)N=C(N)N=C12)N[C@@H](C)C(=O)OCC
InChI
InChIKey=ANSPEDQTHURSFQ-KBPBESRZSA-N
InChI=1S/C21H35N8O6P/c1-5-34-19(30)13(3)27-36(32,28-14(4)20(31)35-6-2)12-33-10-9-29-11-23-16-17(24-15-7-8-15)25-21(22)26-18(16)29/h11,13-15H,5-10,12H2,1-4H3,(H2,27,28,32)(H3,22,24,25,26)/t13-,14-/m0/s1
Rabacfosadine was approved in 2017 under the brand name Tanovea-CA1 for the treatment of canine lymphoma. In addition, this drug has demonstrated effectiveness against non-Hodgkin's lymphoma in dogs, as well as canine cutaneous T-cell lymphoma, and relapsed canine B-cell lymphoma. Rabacfosadine a prodrug, which is hydrolyzed intracellularly to the metabolites, 9-(2-phosphonylmethoxyethyl)-N6-cyclopropyl-2,6-diaminopurine (cPrPMEDAP) and 9-(2-phosphonylmethoxyethyl) guanine (PMEG). PMEG is then converted to its active phosphorylated form, which is a chain-terminating inhibitor of the replicative deoxyribonucleic acid (DNA) polymerases.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=407d42d7-2e23-4e90-aff0-b8b05d226e4b
Curator's Comment: in dogs
Administer TANOVEA-CA1 at 1 mg/kg body weight as a 30-minute intravenous infusion, once every three weeks, for up to five doses. Stepwise dose reductions to 0.8 mg/kg and 0.66 mg/kg or dose delays may be used to manage adverse reactions.
Route of Administration:
Intravenous
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C274
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2003595
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY | |||
|
16047979
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY | |||
|
CHEMBL1823518
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY | |||
|
DB12762
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY | |||
|
M39BO43J9W
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY | |||
|
C152134
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY | |||
|
9943
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY | |||
|
859209-74-8
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY | |||
|
m12243
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY | |||
|
M39BO43J9W
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY | |||
|
300000023721
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY | |||
|
Rabacfosadine
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY | |||
|
DTXSID10235245
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY | |||
|
AB-137
Created by
admin on Sat Dec 16 17:25:14 GMT 2023 , Edited by admin on Sat Dec 16 17:25:14 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)
SUBSTANCE RECORD
